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Abstract 
Purpose: To evaluate the efficacy of orally administered Cymbopogon citratus, Zingiber officinale and 
Syzygium aromaticum essential oils (EOs) in mice infected with Trypanosoma cruzi.  
Methods: Three experiments were conducted with 48 Swiss mice each. The animals were inoculated 
with 2 x 106 metacyclic trypomastigotes of T. Cruzi Y-strain and allocated into the following groups (N = 
12): 1) untreated control; 2) treated with benznidazole (BZ); 3) treated with EO 100 mg/kg; and 4) 
treated with EO 250 mg/kg. The groups were evaluated by fresh blood test, blood culture, conventional 
polymerase chain reaction (PCR), real-time PCR and cure rate (CR).  
Results: All the animals were completely infected with T. cruzi. Treatment with C. citratus and Z. 
officinale EOs altered some of the parameters derived from the parasitemia curve, but CRs did not differ 
from BZ. Treatment with S. Aromaticum EO, on the other hand, not only altered all the parameters 
derived from the parasitemia curve, similar to BZ, but at the dose of 100 mg/kg, CR was also 
significantly higher than BZ.    
Conclusion: The results indicate that the essential oils tested, especially S. aromaticum, exhibited anti-
Trypanosoma cruzi effect and therefore should be investigated for the treatment of Chagas disease.   
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Trypanosoma cruzi is the protozoan parasite 
responsible for the American Trypanosomiasis 
(also known as Chagas disease), which afflicts 
about 6 - 7 million people worldwide. Once 
exclusive to the Americas, where it reached 
endemic status in 21 Latin American countries, 
Chagas disease is currently considered a 
globalized disease [1]. Triatomines are typically 
the main vectors for the transmission of Chagas 
disease in endemic countries. In contrast, a new 
epidemiological scenario seems to be developing 
in Brazil as most of the new cases reported (71 
%) have been acquired by oral route, especially 
in non-endemic regions [1,2]. 
 
Although it is the parasitic disease with the 
greatest impact in the Americas, it is often left 
untreated due to the shortcomings of currently 
available therapies. Based on only two drugs, 
benznidazole and nifurtimox, treatment is long 
and the drugs are highly toxic and poorly 
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tolerated by patients, and its efficacy is 
dependent on the phase of infection [1,3,4]. 
 
Thus, new drugs for the treatment of Chagas 
disease with reduced or no side effects are 
urgently required. Several natural products of 
plant origin from different structural classes have 
been shown to be effective against T. cruzi. 
Different essential oils (EOs) have already been 
tested in vitro against T. Cruzi, demonstrating 
biological activity. Among tested EOs, the 
lemongrass (Cymbopogon citratus) EO has been 
shown to be effective against the amastigote and 
trypomastigote forms of T. cruzi, while the clove 
(Syzygium aromaticum) EO inhibited the growth 
of different epimastigote forms and blood 
trypomastigotes [5-7].  
 
These promising results warrant new studies 
conducted in vivo to better ascertain the efficacy 
of EOs in the treatment of Chagas disease. 
Therefore, the objective of this animal study was 
to evaluate the efficacy of C. citratus, Z. officinale 
and S. aromaticum EOs in mice experimentally 






This study was approved by the Ethics 
Committee on the Use of Animals in 
Experimentation of the State University of 
Maringá, Brazil (CEUA/UEM, resolution no. 
023/2014) and conducted in accordance with the 
international guidelines for the protection of 
animals used for scientific purposes [8]. 
 
Parasites, animals and infection 
 
The T. cruzi Y-strain used in the present study 
was obtained from the strain bank at the Chagas 
disease Laboratory at the State University of 
Maringá. Three experiments, each with 48 
female Swiss mice aged 21 to 28 days and 
weighing between 18 and 20 g, were conducted. 
The animals were kept in micro-acclimated 
cages (Alesco®, 20 x 32 x 21 cm) in a 12 h light-
dark cycle and rodent food and water ad libitum. 
Each animal was inoculated by gavage with 
2x106 metacyclic trypomastigotes obtained from 
the acellular culture suspended in 1 ml of LIT 
medium according to the protocol described by 
Dias et al [9] and modified by Teston et al [10]. 
 
Experimental groups, treatment schedules 
and essential oils 
 
Animals were separated into four groups with 12 
animals each, in such a way that mean weight 
was similar for all four groups. The following 
groups were constituted for each experiment: 1) 
untreated controls (UC); 2) animals treated with 
benznidazole 100 mg/kg (TBZ); 3) animals 
treated with one of the experimental EOs 100 
mg/kg (TEO100); and 4) animals treated with 
one of the experimental EOs 250 mg/kg 
(TEO250). Treatments were initiated on the 5th 
day after inoculation (day) and both BZ and EOs 
were administered by gavage in a single daily 
dose for 20 consecutive days. Lemongrass 
(Cymbopogon citratus; batch 0664), ginger 
(Zingiber officinale; batch 09419), and clove 
(Syzygium aromaticum; batch 09464) EOs were 
obtained by hydrodistillation of plant material 
(Quinari Fragrâncias e Cosméticos LTDA, Brazil) 
and analyzed by gas chromatography coupled to 
mass spectrometry (GC-MS; Shimadzu QP 
2000) under the following conditions: DB-5 
column measuring 30 m x 0.25 mm x 0.25 μm; 
helium 1 ml/min; injector temperature of 240 °C 
and detector temperature of 230°C under the 
following operating conditions: column 
temperature between 50 – 160 °C, at 3 °C/min; 
volume injected of 1 μl (2 mg of the essential oil 
in 1 ml of ethyl acetate). The compounds present 
in the EOs were identified by comparing results 
to the GC-MS (National Institute of Standards 
and Technology - Nist.62 Library) and Kovats 
indices. 
 
Fresh blood test (FBT) 
 
Parasitemia was evaluated daily. Blood was 
collected from the caudal vein of each animal 
from the 3rd day according to Brener [11], until 
zero parasitemia was obtained for three 
consecutive days. FBT was performed to confirm 
infection, plot the parasitemia curve, and 
determine the percentage of animals that were 
FBT positive (%FBT+). At the end of treatment, 
parasitemia was also evaluated on alternate 
days for one week. The following parameters 
derived from the parasitemia curve were 
determined: mean patent period (PP), mean of 
the periods when parasitemia was detected in 
each mouse; maximum parasitemia peak 
(Pmax), calculated from the parasitemia peak 
detected in each mouse in the group; maximum 
peak day (Dpmax), mean of days each mouse 
had Pmax detected; total parasitemia (TP), mean 
of the sum of daily parasitemia of each animal 
throughout the experiment; and the area under 
the parasitemia curve (AUC). 
 
Blood culture (BC) 
 
BC was performed in LIT medium 30 days after 
the end of treatment according to Filardi and 
Brener [12]. Blood samples were collected from 
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the retro-orbital venous plexus of treated 
(TEO100, TEO250 and TBZ) animals and 
untreated controls (UC) to obtain the percentage 
of animals that were BC positive (%BC+). 
 
Conventional polymerase chain reaction 
(cPCR) 
 
cPCR was also performed at 30 days after 
treatment according to Miyamoto et al [13], by 
adding 200 μl of blood to an eppendorf tube 
containing 400 μl of guanidine 6.0 M/EDTA 0.2 M 
solution. The primers 121 (5'AGATAATGCAT 
GA-3') and 122 (5'-GGTTCGATTGGGGTTGGT 
GTAATATA-3') were used to amplify the 330 bp 
fragment of T. cruzi kinetoplast DNA (kDNA) 
minicircles. Samples that generated these 
products were considered positive and were 
observed by electrophoresis in 4.5 % 
polyacrylamide gel and silver staining. Based on 
these results, the percentage of mice that were 
cPCR positive (% cPCR+) was determined. 
 
Qualitative real-time polymerase chain 
reaction (qPCR) 
 
At 115 dai, the cardiac tissue of three animals 
from each experimental group was collected in 
totum. Samples (30 mg/animal) were extracted 
using the chloroform-isopropanol method [14]. 
The obtained DNA was analyzed using SYBR 
green qPCR SuperMix UDG/ROX Platinum 
reagent (Invitrogen, USA) run on the 
thermocycler Rotor Gene Q (Qiagen, Germany) 
[15]. PCR was performed using 100 ng of whole 
genomic DNA (gDNA) and the primers TCZ-F 
(5=-GCTCTTGCCCACAMGGGTGC-3=) and 
TCZ-R (5=-C CAAGCAGCGGATAGTTCAGG-
3=) [16]. Tissue DNA from healthy and Y-strain 
infected mice were used as negative and positive 
controls of extraction, respectively. The mix 
without the genomic DNA was used as negative 
control of amplification. 
 
Determination of infectivity and mortality 
 
Infectivity rate (%INF) was calculated based on 
the number of animals positive for infection in at 
least one of the tests performed (FBT, BC or 
cPCR). Animal survival was registered daily, and 
cumulative mortality rate (%MOR) was calculated 
for each group. 
 
Evaluation of treatment effectiveness 
 
To evaluate the effectiveness of the different 
treatments, cure rates (CRs) were obtained from 
animals treated with the reference drug (BZ) and 
each of the three tested EOs. Animals presenting 
negative results in all the tests were considered 
cured. CRs were obtained by dividing the 
number of cured animals by the total number of 




The data were distributed in frequency tables 
and described in terms of percentages or means. 
Statistical analyzes were performed using the 
software, Bioestat 5.3 (Belém, Pará, Brazil), with 
the significance level set at p < 0.05). 
Proportions were compared using G or Chi-
square test. Means were compared using Mann-
Whitney or Kruskall-Wallis test while AUC was 




Infectivity rate (INF) was 100 % in all 
experimental groups, i.e., all animals inoculated 
with T cruzi Y-strain became infected. 
Cumulative mortality rate (MOR) was 0 %, i.e., 
no animal from any of the groups died during the 
experiments. 
 
Test 1:   Cymbopogon citratus EO 
 
The chromatographic analysis showed that the 
lemongrass EO presented in its composition 46.8 
% of geranial (α-citral) and 33.5 % of neral (β-
citral) as its main constituents. The highest 
parasitemia levels were observed in UC, followed 
by TLEO100, TLEO250, and TBZ. Treatment 
with the reference drug BZ was able to promote 
zero parasitemia in most animals immediately 
after the first day of treatment, and in all animals 
after the third day of treatment. Groups treated 
with TLEO100 and TLEO250 were positive for 
parasitemia for almost the entire treatment 
period. All animals presented negative FBT after 
the end of treatments (Figure 1). 
 
All parameters derived from the parasitemia 
curve, except for Dpmax, presented statistically 
significant differences among groups (p < 0001). 
TBZ presented the lowest values for all 
parameters (p ≤ 0.01). When compared to UC, 
animals treated with TLEO100 and TLEO250 
presented a significant reduction in PP (p < 
0.01), Pmax (p < 0.01), and AUC (p = 0.0178). A 
significant reduction in TP (p ≤ 0.0102) was also 
observed but only in those animals treated with 
TLEO250 (Table 1). The %BC+ varied among 
groups (p < 0.03). TBZ presented the highest 
%BC+, reaching statistical significance when 
compared with TLEO100 and TLEO250 (p = 
0.03). 
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Figure 1: Experiment 1 (treatment started on the 5th day after inoculation). Mean parasitemia curve of mice 
inoculated with Trypanosoma cruzi (Y strain - TcII) treated with benznidazole 100 mg/kg/day (TBZ; □), 
Cymbopogon citratus essential oil at the doses of 100 mg/kg/day (TLEO100; ▲) and 250 mg/kg/day (TLEO250; 
×), during 20 consecutive days, and untreated controls (UC; ◊) 
 
Table 1: Statistical comparisons of parasitological and molecular parameters, and cure rates in mice inoculated 
with Trypanosoma cruzi (Y-strain - TcII), treated with benznidazole  (TBZ), Cymbopogon citratus essential oil at 
the doses of 100 mg/kg/day (TLEO100) and 250 mg/kg/day (TLEO250), during 20 consecutive days, and 
untreated controls (UC) 
 
Parameter UC TBZ TLEO100 TLEO250 P-value* 
PP 9.8 ± 1.3 0.2 ± 0.4 6.8 ± 2.9 6.1 ± 2.6 <0.0001 
Pmax  3181.8 ± 1545.2 254.6 ± 540.0 2450.0 ± 2541.5 1750.0 ± 633.2 <0.0001 
Dpmax  14.3 ± 2.3 6.5 ± 0.5 11.6 ± 3.5 13.0 ± 0.6 NS 
TP  9672.7 ± 4577.6 233.3 ± 544.9 6883.3 ± 5010.8 5133.3 ± 1823.7 <0.0001 
AUC  11136.3 ± 5533.6 233.3  ± 544.9 7991.7 ± 5393.0 5950.0 ± 2203.5 <0.0001 
%BC+ 50.0 (4/8) 75.0 (6/8) 37.5 (3/8) 22.2 (2/9) 0.03 
%cPCR+ 100.0 (5/5) 0.0 (0/1) 20.0 (1/5) 85.7 (6/7) 0.02 
%qPCR+ 0.0 (0/3) 0.0 (0/3) 0.0 (0/3) 33.3 (1/3) NS 
Cure rate - 12.5 (1/8) 50.0 (4/8) 11.1 (1/9) NS 
PP: patent period (in days); Pmax: parasitemia peak (number of trypomastigotes/0.1 ml of blood); Dpmax 
maximum peak day; TP: total parasitemia; AUC: area under the curve; %BC+: percentage of animals with 
positive blood culture; %cPCR+: percentage of animals cPCR positive; %qPCR+: percentage of animals with 
qPCR positive; NS = not significant. * P ≤ 0.05 was considered significant. G or Chi-square tests were used for 
the analysis of proportions, while Mann-Whitney or Kruskall-Wallis tests were used for means analysis 
 
cPCR confirmed infection in 4 animals in the UC 
group, which had previously been FBT+ but were 
BC-. The %cPCR+ also varied among groups (p 
= 0.03), being smallest in the TBZ group. In 
TLEO250 group, cPCR+ was observed in 6/7 
animals (85.7%). Tissue analysis performed on 
cardiac samples from three animals of each 
group, showed qPCR+ only in one mouse in the 
TLEO250 group, which was also cPCR+. CRs 
obtained from animals treated with lemongrass 
EO did not significantly differ from animals 
treated with BZ. These results demonstrated that 
mice orally inoculated with T. cruzi Y-strain 
responded poorly to treatment with both the 
lemongrass EO (in both dosages) and the 
reference drug (BZ) (Table 1). 
 
Test 2: Zingiber officinale EO 
 
Chromatographic analysis showed that the main 
constituents of the ginger EO were α-pinene 
(17.9 %), β-pinene (14.9 %) and zingiberene 
(14.7 %). FBT was negative for all the animals in 
the TBZ group. As a result, the animals in the 
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TBZ group presented null values in all five 
parameters derived from the parasitemia curve. 
Significant differences were observed among 
groups (p < 0.0001) in 4/5 of the parasitemia 
parameters. When compared to UC, animals 
treated with TGEO100 and TGEO250 
demonstrated a significant reduction in PT (p = 
0.02) and AUC (p = 0.04) (Figure 2). BC and 
cPCR confirmed infectivity in 100 % of the 
animals tested, including those in the TBZ group. 
However, no significant differences in %BC+ and 
%cPCR+ were observed among the groups. CR 
for BZ-treated animals was zero, showing once 
again that the reference drug was not effective in 
the animals orally inoculated with the T. cruzi Y-
strain. CRs obtained from animals in the 
TGEO100 and TGEO250 groups were not 
significantly different from BZ. Although %qPCR+ 
was numerically highest in the TGEO250 group 
and lowest in the TBZ group, no statistical 






























Figure 2: Experiment 2 (treatment started on the 5th day after inoculation). Mean parasitemia curve of mice 
inoculated with Trypanosoma cruzi (Y strain - TcII) treated with benznidazole 100 mg/kg/day (TBZ; □), Zingiber 
officinale essential oil at the doses of 100 mg/kg/day (TGEO100; ▲) and 250 mg/kg/day (TGEO250; ×), during 
20 consecutive days, and untreated controls (UC; ◊) 
 
Table 2: Statistical comparisons of parasitological and molecular parameters, and cure rates in mice inoculated 
with Trypanosoma cruzi (Y-strain - TcII), treated with benznidazole  100 mg/kg/day (TBZ), Zingiber officinale 
essential oil at the doses of 100 mg/kg/day (TGEO100) and 250 mg/kg/day (TGEO250), during 20 consecutive 
days, and untreated controls (UC). 
 
Parameter UC TBZ TGEO100 TGEO250  P-value* 
PP  6.4 ± 2.9 0.0 4.3 ± 3.1 4.6 ± 3.4 <0.0001 
Pmax  2800 ± 2067.9 0.0 1400.0 ± 596.9 1983.3 ± 1260.5 <0.0001 
Dpmax  13.8 ± 2.1 0.0 13.5 ± 1.9 13.4 ± 1.3 NS 
TP  8866.7 ± 7146.9 0.0 3266.7 ± 2096.5 5133.3 ± 4235.2 <0.0001 
AUC  10208.3 ± 8000.5 0.0 3558.3 ± 2320.8 5425.0 ± 4776.9 <0.0001 
%BC+ 55.6 (5/9) 75.0 (6/8) 55.6 (5/9) 66.7 (6/9) NS 
%cPCR+ 100.0 (4/4) 100.0 (2/2) 50.0 (2/4) 100.0 (2/2) NS 
%qPCR+ 33.3 (1/3) 0.0 (0/3) 33.3 (1/3) 66.6 (2/3) NS 
Cure rate - 0.0 (0/8) 22.2 (2/9) 11.1 (1/9) NS 
PP: patent period (in days); Pmax: parasitemia peak (number of trypomastigotes/0.1 ml of blood); Dpmax 
maximum peak day; TP: total parasitemia; AUC: area under the curve; %BC+: percentage of animals with 
positive blood culture; %cPCR+: percentage of animals cPCR positive; %qPCR+: percentage of animals with 
qPCR positive; NS = not significant. *Values of p ≤ 0.05 were considered significant. The G or chi-square tests 
were used for the analysis of proportions, and the Mann-Whitney or Kruskall-Wallis tests for means analysis 
 
Test 3: Syzygium aromaticum EO 
 
The major constituents identified in the clove EO 
were eugenol and β-caryophyllene at 
concentrations of 82.9 % and 13.0 %, 
respectively. UC group demonstrated the highest 
parasitemia level (p < 0.0100) when compared to 
the other groups (Figure 3). Only one animal in 
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the TBZ group presented PP and, as a result, all 
the parameters derived from the parasitemia 
curve were significantly lower in this group when 
compared with the other groups (p < 0.0001). 
When compared to UC, animals in the TCEO100 
and TCEO250 groups presented reduced PP, 
Pmax, Dpmax, PT and AUC values. The %BC+ 
varied among groups, being highest for the TBZ 
group and lowest for the TCEO250 group (p = 
0.01). However, %cPCR+ and %qPCR+ 
presented no significant differences. None of the 
animals treated with BZ was cured. CRs 
demonstrated significant differences among 
groups (p = 0.03). CR induced by the clove EO 
(TCEO100) was significantly higher than that 




Figure 3: Experiment 3 (treatment started on the 5th day after inoculation). Mean parasitemia curve of mice 
inoculated with Trypanosoma cruzi (Y strain - TcII) treated with benznidazole 100 mg/kg/day (TBZ; □), Syzygium 
aromaticum essential oil at the doses of 100 mg/kg/day (TCEO100; ▲) and 250 mg/kg/day (TCEO250; ×), during 
20 consecutive days, and untreated controls (UC; ◊) 
 
Table 3: Statistical comparisons of parasitological and molecular parameters, and cure rates in mice inoculated 
with Trypanosoma cruzi (Y-strain - TcII), treated with benznidazole  100 mg/kg/day (TBZ), Syzygium aromaticum 
essential oil at the doses of 100 mg/kg/day (TCEO100) and 250 mg/kg/day (TCEO250), during 20 consecutive 
days, and untreated controls (UC) 
 
Parameter UC TBZ TCEO100 TCEO250 P-value* 
PP (days) 12.6 ± 2.9 0.1 ±  0.3 6.1 ± 4.3 5.2 ± 3.2 <0.0001 
Pmax  5367.0 ± 1872 116.7 ± 386.9 3877.0 ± 2073.0 3446.0 ± 2466.0 <0.0001 
Dpmax  12.7 ± 1.4 5.0 ± 0.0 11.2 ± 1.5 11.3 ± 2.0 <0.0001 
TP 28233.0 ± 9455 0.0 ± 0.0 8723.0 ± 5516.0 8185.0 ± 6152.0 <0.0001 
AUC  32675 ± 11194.7 58.3 ± 202.1 10507.6 ± 6222.7 10146.1 ± 7543.9 <0.0001 
%BC+ 55.6 (5/9) 77.8 (7/9) 22.2 (2/9) 11.1 (1/9) 0.01 
%cPCR+ 77.8 (7/9) 77.8 (7/9) 55.6 (5/9) 66.7 (6/9) NS 
%qPCR+ 33.3 (1/3) 0.0 (0/3) 0.0 (0/3) 0.0 (0/3) NS 
Cure rate - 0.0 (0/9) 44.4 (4/9) 22.2 (2/9) 0.03 
PP: patent period (in days); Pmax: parasitemia peak (number of trypomastigotes/0.1 ml of blood); Dpmax 
maximum peak day; TP: total parasitemia; AUC: area under the curve; %BC+: percentage of animals with 
positive blood culture; %cPCR+: percentage of animals cPCR positive; %qPCR+: percentage of animals with 
qPCR positive; NS = not significant. *Values of p ≤ 0.05 were considered significant. The G or chi-square tests 




Chagas disease is one of 17 neglected tropical 
infirmities listed by the World Health 
Organization, with less than 1 % of infected 
people estimated to receive adequate treatment. 
Currently available drugs, benznidazole and 
nifurtimox, can cure infected patients but are 
effective only at the beginning of the infection 
depending on the genetic variation of T. cruzi. 
Moreover, treatment is long with several adverse 
effects, which results in high rates of 
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nonadherence [17]. Products derived from 
medicinal plants may lead the way into the 
discovery of new drugs, or combination of drugs, 
for the treatment of Chagas Disease. Indeed, 
several studies support the therapeutic value of 
different natural products of plant origin as 
trypanocidal agents [6,7,18]. 
 
In the present study, the effectiveness of three 
different essential oils (EOs) was evaluated in 
the treatment of mice orally infected with T. cruzi. 
Three separate tests were conducted following 
the same design, comparing the results obtained 
with each EO at the doses of 100 and 250 mg 
with the results of untreated controls (UC) and 
animals treated with the reference drug (BZ). 
Seven parasitological parameters, five of them 
related to the parasitemia curve (PP, Pmax, 
Dpmax, TP, and AUC), and two assessing the 
presence of the parasite in the blood (FBT, and 
BC); two molecular analysis, one performed in 
blood (cPCR) and one in the cardiac tissue 
(qPCR); and the cure rates (CRs) of different 
treatments were analysed. All inoculated animals 
became infected and no deaths were recorded 
during the follow-up period. 
 
The T. cruzi Y-strain of TcII DTU [19] is 
considered highly virulent for albino mice [20]. 
Apart from being partially resistant to 
benznidazole and nifurtimox, it presents high 
infectivity, parasitemia and lethality in mice. As a 
result, the Y-strain has been widely used in 
different types of studies, including those 
screening for new drugs for the treatment of 
Chagas disease. In the present study, low levels 
of parasitemia and zero mortality were observed 
with the oral administration of this strain. This 
biological behavior was quite different from that 
previously observed in mice inoculated both 
intraperitoneally and orally. In a study performed 
by our group using the same inoculum and 
inoculation route, mortality rate of 90 %, and 
Pmax, PT and AUC values approximately 40-fold 
higher than in the current study were observed 
[9]. Differences may be due to the prolonged 
maintenance of the strain in LIT acellular culture 
medium without blood passages in mice, which 
may have led to a reduction of the Y-strain 
virulence in the present study. This is consistent 
with the low %qPCR+ found in the cardiac tissue 
of the animals tested. T. cruzi Y-strain is 
biologically heterogeneous and some 
subpopulations (clones) can be selected after 
years of laboratory storage [21]. Nonetheless, 
other biological characteristics of the orally 
administered Y-strain were maintained, such as 
PP duration (around 10 days), Dpmax (around 
day 14), and high infectivity (100 % of inoculated 
animals became infected) [22].  
The three EOs evaluated in this study altered the 
parasitemia curve profile, demonstrating reduced 
values of different parameters when compared to 
the UC group. The use of BZ and TCEO in the 
two tested doses reduced all the five parameters, 
indicating a superior suppressive effect on 
parasitemia than TLOE and TGOE. However, 
animals treated with BZ presented significantly 
higher %BC+ (75 %) than animals in the TLEO 
and TCEO groups. A possible explanation for 
this result would be that blood trypomastigote 
forms of the Y-strain are more sensitive to BZ 
than tissue amastigotes. Moreover, as BC was 
performed 30 days after the end of the 
experiment, %BC+ might have started to rise 
again after the pressure exerted by the drug on 
parasitemia was ceased. Alternatively, EO 
penetrating power into tissues might have been 
greater than BZ, reaching tissue amastigote 
forms more effectively.   
 
The highest CRs after treatment were 50 % (4/8) 
obtained with TLEO100 and 44.4 % (4/9) with 
TCEO100. Lemongrass and clove EOs also 
promoted the reduction of most parameters 
evaluated (6/8). Although BZ presented higher 
suppressive effect on parasitemia, CRs found 
suggest greater effectiveness of these two EOs, 
mainly in the elimination of tissue amastigotes. 
These results place the lemongrass and clove 
EOs, and their major components, among the 
potential candidates for the treatment of patients 
orally infected with T. cruzi. 
 
The biological activity of natural products is 
directly related to their constituents.  Lemongrass 
(C. citratus), ginger (Z. officinale) and clove (S. 
aromaticum) EOs main constituents are terpenes 
and terpenoids, which have already been shown 
to have in vitro activity against the protozoan 
responsible for Chagas disease [7,23]. Promising 
therapeutic effects of the C. citratus EO have 
already been demonstrated in vitro on the genus 
Trypanosoma [24] and T. cruzi [5]. Moreover, 
extracts prepared from ginger have also shown 
trypanocidal activity against T. evansi [25], while 
ginger and lemongrass oils were effective 
against four Leishmania species [26]. The effect 
obtained with the use of lemongrass EO on 
parasitemia in the present study, although 
inferior to BZ, can be attributed to its major 
constituents, geranial (α-citral) and neral (β-
citral), which have already demonstrated in vitro 
activity against T. cruzi epimastigotes and 
trypomastigotes [27]. In an in vivo study, the 
Aloysia triphylla EO also demonstrated activity 
against T. cruzi, and the authors attributed this 
effect to these same substances found in the 
lemongrass EO [28].   
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Among the EOs tested in this study, the clove 
EO presented the most promising results. The 
CR found with the use of clove EO (44.4%), 
while still far from ideal, was higher than that 
obtained with BZ (0.0%). This result can be 
attributed to its compounds, eugenol and 
caryophyllene, which represent almost the totality 
of the constituents identified. They have already 
demonstrated antiparasitic effect in vitro against 
promastigotes forms of Leishmania and 
epimastigotes forms of T. cruzi, with 
caryophyllene, in particular, presenting better 
clinical activity against the two parasites [29]. 
 
In this study, the efficacy of the different 
treatments on the animals orally inoculated with 
T. cruzi was monitored with parasitological (FBT 
and BC) and molecular techniques (cPCR in 
blood, and qPCR in cardiac tissue). Moreover, 
the animals were not subjected to 
immunosuppression with cyclophosphamide, as 
currently recommended for cure control of 
experimental chemotherapy of T. cruzi infection. 
Regarding the molecular analyzes, our results 
showed that cPCR in blood presented greater 
detection capacity of T. cruzi DNA than qPCR 
performed in the cardiac tissue. The %qPCR+ 
results indicate that the capability of Y-strain 
tested to invade the tissue was low. When 
applied in blood, the same technique has 
demonstrated higher detection capability than 
cPCR in mice orally inoculated with TcIV strains 
obtained from oral infection outbreaks in the 
Amazon [10]. These differences may be related 
to the genetic content of the parasite DTUs, the 
different targets of the two PCR protocols, and 
the biological material used in the analyses 
(blood and cardiac tissue). The amount of 
parasites and the period over which the tests 
were performed may also vary. In the present 
study, blood analyzed with cPCR was collected 
55 dai, while cardiac tissue was collected 115 
dai.  
 
Mice orally inoculated with the Y-strain did not 
respond to BZ treatment, with cure rates varying 
from 0 % to 12.5 % (mean of 4.2 %). This is in 
contrast with the CRs around 50 % (30-70 %) 
obtained with mice inoculated intraperitoneally, 
the classic route used by researchers, with the 
same strain and inoculum [12,22,30]. This 
suggests that the Y-strain is partially resistant to 
BZ in vivo when inoculated intraperitoneally, and 
even less susceptible to the drug when 
inoculated orally. Thus, the orally inoculated Y-
strain in the present study was shown to be 
resistant to BZ. This is in agreement with results 
previously obtained by our group, which showed 
that mice orally infected with T. cruzi (TcIV 
strains), not only presented more severe 
infection, but also responded worse to BZ 





Our results showed that the orally inoculated Y 
strain of T. cruzi is resistant to BZ. All the 
essential oils tested altered the parasitemia 
curve parameters, but benznidazole had greater 
suppressive effect. Treatment with S. 
aromaticum EO at the dose of 100 mg proved to 
be promising in the treatment of T. cruzi 
infection, being more effective than the reference 
drug. Further studies are required to investigate 
S. aromaticum EO in order to evaluate the 
toxicity and efficacy of its major components in 
vivo, both alone and in association with other 
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